Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20120520009801N11
IRCT20120520009801N11
Not Yet Recruiting
Phase 3

Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and Ecocardiography parameters in patients with congenital heart diseases with left-to-right shunt: a triple-blind, randomized, placebo-controlled trial

Mashhad University of Medical Sciences0 sites44 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Mashhad University of Medical Sciences
Enrollment
44
Status
Not Yet Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients with congenital heart diseases with left\-to\-right shunt
  • •Heart failure
  • •One month to 18 years

Exclusion Criteria

  • •Patients with various types of cardiomyopathy
  • •Patients with myocarditis
  • •Patients with pericarditis and cardiac tamponade
  • •Patients with thiamine deficiency (beriberi) based on clinical symptoms
  • •Patients with severe anemia
  • •Patients with thyrotoxicosis
  • •Presence of pulmonary infection
  • •?Chronic kidney disease in GFR \< 20 ml/min/173 m2
  • •?Patients on dialysis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Effect of Empagliflozin in prevention of kidney stone parameters
IRCT20211203053261N2Hamedan University of Medical Sciences138
Not Yet Recruiting
Phase 3
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patients
CTRI/2024/02/063292SRM Insitute of Science and Technology
Completed
Phase 1
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8
IRCT20150706023084N18Islamic Azad University30
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02
IRCT20220902055858N1Shahre-kord University of Medical Sciences90
Recruiting
Phase 3
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function tests
IRCT20191209045671N3Semnan University of Medical Sciences60